Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Diversified Biopharma sector at J.P Morgan
For type 2 diabetes, NICE guidance (NG28) recommends their use as second- or third-line therapy when metformin alone provides inadequate control, particularly in patients who would benefit from weight loss or where hypoglycaemia risk must be minimised
The most commonly reported side effect is nausea, which feels like motion sickness or morning sickness, says Dr
As a glucagon-like peptide-1 (GLP-1) receptor agonist, GLP-1 Treatments, Semaglutide or Tirzepatide mimics the action of the body's natural GLP-1 hormone
2 Additionally, GLP-1 receptor agonists have the added benefit of weight loss
Results vary depending on the medication used, consistency, body composition, nutrition, activity level, and overall metabolic health
US$ 21.38
US$ 24.01
US$ 26.01
US$ 22.49
US$ 20.10
US$ 29.86
US$ 22.28
US$ 26.88
US$ 28.61
US$ 27.77
US$ 25.78
